10.96  0.81 (7.98%)		08-27 00:00
Open: 10.2 High: 11.27 Volume: 295,507		Pre. Close: 10.15 Low: 10.17 Market Cap: 1,130(M)

Short term
Mid term
Targets	6-month :	11.73	1-year :	13.71
Resists	First :	10.05	Second :	11.73
Pivot price	10.04
Supports	First :	10.01	Second :	10
MAs	MA(5) :	10.05	MA(20) :	10.04
	MA(100) :	9.96	MA(250) :	9.88
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	100	D(3) :	100
RSI	RSI(14): 67.2
52-week	High :	10.05	Low :	9.72

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ HAAC ] has closed below upper band by 43.3%. Bollinger Bands are 74.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	10.07 - 10.12	10.12 - 10.16
Low:	9.9 - 9.97	9.97 - 10.02
Close:	9.95 - 10.06	10.06 - 10.14

Alpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Mon, 07 Aug 2023
Carmell Therapeutics begins public trading - Pittsburgh Post-Gazette

Mon, 04 Apr 2022
The Matrix Recellularized: Humacyte Manufactures Bioengineered Human Tissues at Commercial Scale - Genetic Engineering & Biotechnology News

Fri, 03 Sep 2021
De-SPACs are Falling as PIPE Shares Open Up for Sale - TheStreet

Fri, 27 Aug 2021
Humacyte Combines with Alpha Healthcare in Latest Biopharma SPAC - BioSpace

Mon, 22 Feb 2021
Humacyte agrees SPAC merger to go public with bioengineered tissue tech - Pharmaceutical Technology

Wed, 17 Feb 2021
Humacyte sets out to bring regenerative medicine to Wall Street, then the world - MedCity News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	53 (M)
Shares Float	45 (M)
Held by Insiders	0 (%)
Held by Institutions	82.5 (%)
Shares Short	194 (K)
Shares Short P.Month	244 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.88
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-11.43
Price to Sales	0
Price to Cash Flow	-204.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.